A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for ...

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an ...

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised ...

Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” ...